Clinical Status and Optimal Use of the Cardioprotectant, Dexrazoxane
ثبت نشده
چکیده
The anthracycline antitumor antibiotics are important chemotherapeutic agents for the treatment of leukemias, lymphomas, breast cancer, myeloma, small-cell lung cancer, sarcomas, bladder cancer, and pediatric solid tumors. However, the clinical usefulness of the anthracycline antibiotics is limited by their cardiac toxicity, and clinicians confront a clinical dilemma as they balance the efficacy of longer duration of treatment against the cardiac toxicity associated with cumulative doses.
منابع مشابه
Clinical status and optimal use of the cardioprotectant, dexrazoxane.
There are many challenges facing those involved in chemotherapy drug development. In addition to identification of new agents, clinical investigators must address questions regarding the optimal methods of administration of established agents so as to maximize efficacy and minimize toxicity. Treatment toxicity affects not only morbidity and mortality but also issues of dose intensity, quality o...
متن کاملUse of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
GUIDELINE QUESTIONS 1) Should dexrazoxane be used routinely in patients with advanced or metastatic cancer who are at risk of developing cardio toxicity when receiving chemotherapy containing doxorubicin or epirubicin? 2) Do the available data support the use of dexrazoxane when anthracyclines are being used in the adjuvant setting for patients at risk of developing cardiotoxicity? OBJECTIVE ...
متن کاملMultiple myeloma and its treatment.
Mr. F received several different treatment regimens for MM. He required a cardioprotectant, dexrazoxane, to continue treatment with the VAD regimen. He received interferon, high-dose chemotherapy with tandem stem cell transplants, and newer agents used in the treatment of MM, such as thalidomide and topotecan. However, as illustrated by Mr. F's case study, MM remains an incurable disease despit...
متن کاملDexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: analysis of a national cohort of patients in the Pediatric Health Information Systems database.
BACKGROUND Acute lymphoblastic (ALL) and myeloid leukemia (AML) account for approximately 26% of pediatric cancers. Anthracyclines are widely used to treat these leukemias, but dosing is limited by cardiotoxicity. Data support the efficacy of dexrazoxane as a cardioprotectant in children; however, dexrazoxane use in children is not universally accepted due to concerns about toxicity, impact on ...
متن کاملDexrazoxane for Preventing Anthracycline Cardiotoxicity in Children with Solid Tumors
This study attempted to assess the incidence and outcome of anthracycline cardiotoxicity and the role of dexrazoxane as a cardioprotectant in childhood solid tumors. The dexrazoxane group included 47 patients and the control group of historical cohort included 42. Dexrazoxane was given in the 10:1 ratio to doxorubicin. Fractional shortening and systolic and diastolic left ventricular diameters ...
متن کامل